On February 10, 2026, Fred Roeder released an analysis of the 340B Drug Discount Program, highlighting concerns about its current structure and suggesting possible reforms. The article was published by the Consumer Choice Center and is available here.
The analysis outlines how the program, originally intended to help hospitals and clinics support patients in need by allowing them to purchase medicines at lower prices, has grown more complex over time. Roeder said that the program now involves many pharmacies, various methods of dispensing medicines, and a large industry of middlemen whose business depends on processing more 340B activity.
According to Roeder, "The biggest flaw is this: In the current setup, the decision about whether a prescription qualifies for the 340B price is often made after the medicine is already given to the patient. This is important because the lower 340B price is supposed to be limited to specific situations. The rules say a hospital or clinic should not use the discount for people who are not truly their patients. The rules also say a drug company should not be forced to give two discounts on the same prescription through different government or insurance discount programs."
Roeder explained that when eligibility decisions are made after dispensing medication, it becomes difficult for drug companies to verify if prescriptions qualify before financial transactions occur. He said this system relies on trust rather than upfront verification and can lead to double discounts—where both a 340B discount and another government or insurance discount are applied to one prescription.
The article discusses why common solutions such as billing tags or audits do not consistently prevent these issues before discounts are applied. Roeder proposes a rebate model as an alternative: "A rebate model simply changes the order of operations. Instead of giving the discounted price first and checking later, you check first and then pay the discount only when it is proven to be eligible." He added that this approach would tie discounts directly to verified eligibility rather than assumptions.
Roeder concluded that while some may see this as creating new burdens for hospitals or clinics, in practice it represents more of a timing change than an additional administrative load. He said that verifying prescription eligibility before applying discounts could ensure that benefits reach patients rather than remaining with healthcare providers.
Alerts Sign-up